×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Alkem Laboratories Limited | 24887.5 | 6561.6 | 23721.7 | 52.04 | 63,764 | 28.0 |
| AUROBINDO PHARMA LTD. | 29319.4 | 5591.3 | 28481.7 | 9.63 | 61125 | 18.1 |
| GLENMARK PHARMACEUTICALS LTD. | 24642.63 | 3302.26 | 23949.28 | 11.7 | 57874 | 43.5 |
Alkem Laboratories Limited, with Security Code 539523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,238.0 | 2,253.2 | 2,634.6 | 2,494.6 | 2,365.4 | 2,500.1 | 2,872.0 | 2,286.8 | 2,044.9 | 2,372.2 |
| Expenses | 1,906.0 | 1,919.4 | 1,980.0 | 1,925.3 | 1,957.9 | 1,879.5 | 2,144.3 | 1,629.0 | 1,748.2 | 1,751.7 |
| Operating Profit | 332.0 | 333.8 | 654.6 | 569.3 | 407.5 | 620.6 | 727.6 | 657.8 | 296.8 | 620.5 |
| OPM % | 14.83% | 14.81% | 24.85% | 22.82% | 17.23% | 24.82% | 25.34% | 28.77% | 14.51% | 26.16% |
| Other Income | 76.6 | 64.7 | 61.8 | 44.4 | 71.3 | 106.1 | 120.2 | 169.2 | 111.6 | 130.9 |
| Interest | 21.7 | 21.4 | 18.7 | 21.1 | 20.7 | 21.4 | 17.6 | 21.0 | 16.9 | 12.8 |
| Depreciation | 57.2 | 58.1 | 59.0 | 58.1 | 69.1 | 64.4 | 62.6 | 67.6 | 91.6 | 58.9 |
| Profit before tax | 329.7 | 318.9 | 638.7 | 585.7 | 401.5 | 640.9 | 767.7 | 738.4 | 299.8 | 665.4 |
| Tax % | -22.7% | -14.9% | 1.2% | -5.6% | -16.5% | 9% | -9.1% | -8.4% | -24.6% | 8.4% |
| Net Profit | 254.8 | 271.4 | 646.5 | 504.2 | 325.0 | 583.3 | 697.6 | 723.1 | 276.9 | 656.2 |
| EPS in Rs | 21.31 | 22.7 | 54.07 | 42.17 | 27.18 | 48.78 | 58.34 | 60.48 | 4.28 | 54.88 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,040.9 | 2,902.6 | 2,967.7 | 3,440.2 | 3,323.9 | 2,935.8 | 3,031.8 | 3,414.7 | 3,374.3 | 3,143.8 |
| Expenses | 2,441.9 | 2,549.4 | 2,578.5 | 2,693.4 | 2,616.3 | 2,533.8 | 2,423.2 | 2,661.8 | 2,614.9 | 2,753.0 |
| Operating Profit | 599.1 | 353.3 | 389.2 | 746.7 | 707.6 | 402.0 | 608.6 | 752.8 | 759.4 | 390.7 |
| OPM % | 19.7% | 12.17% | 13.11% | 21.71% | 21.29% | 13.69% | 20.08% | 22.05% | 22.51% | 12.43% |
| Other Income | 45.3 | -34.3 | 65.8 | 5.5 | 42.3 | 75.7 | 120.3 | 134.5 | 93.0 | 146.0 |
| Interest | 27.1 | 29.0 | 29.8 | 30.3 | 25.5 | 26.9 | 29.1 | 28.1 | 36.0 | 28.4 |
| Depreciation | 78.4 | 78.3 | 72.4 | 73.9 | 69.6 | 83.4 | 80.5 | 78.9 | 85.3 | 112.5 |
| Profit before tax | 538.9 | 314.6 | 352.9 | 705.7 | 706.2 | 379.9 | 619.4 | 780.3 | 731.1 | 395.8 |
| Tax % | -14.6% | -68% | -18.4% | -5.1% | -7.7% | -17.1% | -11.2% | 10% | 12.3% | -18.5% |
| Net Profit | 460.0 | 67.7 | 287.8 | 614.9 | 604.3 | 304.5 | 550.2 | 702.0 | 640.8 | 322.4 |
| EPS in Rs | 38.03 | 5.94 | 23.98 | 51.9 | 49.76 | 24.55 | 45.6 | 57.6 | 52.34 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 16% |
| 3 Years: | 22% |
| 1 Year: | -3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 11% |
| 3 Years: | 13% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 20% |
| 3 Years: | 7% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 16% |
| 3 Years: | 22% |
| 1 Year: | -3% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|